{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-011011","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2024-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.059725+00:00","generated_at":"2026-06-06T09:21:36.764636+00:00","sec_items":["7.01","9.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rani announces positive Phase 1 topline results for oral ustekinumab biosimilar RT-111","bullets":["RT-111 achieved 84% bioavailability vs subcutaneous Stelara injection; higher Cmax and shorter Tmax observed.","No serious adverse events; mild transient AEs resolved without intervention; no participants withdrew.","Celltrion holds right of first negotiation to acquire worldwide rights to RT-111 after successful Phase 1.","This marks Rani's third successful Phase 1 trial using RaniPill technology; potential differentiated oral dosing for psoriasis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-011011","json":"https://secwatch.observer/filing/0000950170-24-011011.json","markdown":"https://secwatch.observer/filing/0000950170-24-011011.md","text":"https://secwatch.observer/filing/0000950170-24-011011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017024011011/0000950170-24-011011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017024011011/rani-20240205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:21:36.764636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}